RADNOSTIX, INC.

RADNOSTIX, INC. has a liquidity position that is below the typical threshold for financial stability, with a current ratio of 0.7. The company's cash and equivalents amount to $2,368,500, while its operating cash flow is positive at $412,440. However, the free cash flow is negative at -$223,520, indicating that capital expenditures are outpacing operating cash flow. The company's profitability is currently negative, with a return on equity of -3.82% and a return on assets of -0.92%. These figures are below the typical performance metrics for the pharmaceuticals industry, suggesting that the company is not generating returns that meet industry standards. RADNOSTIX, INC. does not disclose specific segments or geographic regions in its financial reporting, making it difficult to assess revenue concentration or geographic exposure. The lack of detailed segment reporting limits the ability to evaluate the company's diversification and risk exposure across different markets. The company's growth trajectory is uncertain, as it has reported a net loss of $154,050 and an operating loss of $266,190. The outlook for the current fiscal year does not provide specific numeric deltas for revenue growth, but the negative net income suggests that the company is not currently expanding its revenue base. The risk assessment indicates a low level of liquidity and dilution risk. There are no immediate filing-based liquidity or dilution flags, and the company's capital structure does not show signs of near-term dilution pressure. The debt-to-equity ratio of 0.49 suggests a relatively conservative capital structure, with a manageable level of long-term debt. There are no recent events or filings that have been disclosed in the provided data, which limits the ability to assess the company's recent performance or strategic direction. The absence of recent transcripts or filings means that the company's operational and financial developments cannot be evaluated in detail.